Review Article of International Journal of Nanoparticle Research
Fluodot Nanoparticle – A Promising Novel Delivery System For Veterinary Vaccine
Aseno Sakhrie1, Jingwen Ding2, Ankarao Kalluri2, Zeinab Helal1, Challa V. Kumar2 and Mazhar I. Khan1*
1Department of Pathobiology and Veterinary Science, Institute of Materials Science, University of Connecticut, Storrs CT 06269 USA; 2Department of Chemistry, Department of Molecular and Cell Biology, University of Connecticut, Storrs CT 06269 USA
Most of the killed, inactivated, or live-attenuated pathogen vaccines are now replaced by modern vaccines containing isolated, highly purified antigenic protein subunits which are safer than live viruses or deactivated viruses. Another strategy is the development of nanoparticles which can mimic the repetitiveness, geometry, size and shape of the host-pathogen surface and provide improved stability and long lasting immunogenicity, as well as serve as vehicles to deliver multiple copies of the antigens to the target cells. Several interesting advances have been made recently in the area of protein nanotechnology and here, we provide a concise review of one such novel nanoparticle called FluoDot which may be effectively used as a delivery system in some veterinary medicine applications.
Keywords: FluoDot; Nanoparticle; Protein: Vaccine
How to cite this article:
Aseno Sakhrie, Jingwen Ding, Ankarao Kalluri, Zeinab Helal, Challa V. Kumar and Mazhar I. Khan. Fluodot Nanoparticle – A Promising Novel Delivery System For Veterinary Vaccine. International Journal of Nanoparticle Research, 2020; 3:14. DOI: 10.28933/ijonr-2020-08-1205
1. Crivelli B, Perteghella S, Bari E, Sorrenti M, Tripodo G, Chlapanidas T, Torre M L. (2018) Silk Nanoparticles: From Inert Supports to Bioactive Natural Carriers for Drug Delivery. Soft Matter, 14 (4), 546–557. DOI:10.1039/C7SM01631J.
2. Verma D, Gulati N, Kaul S, Mukherjee S, Nagaich U. (2018). Protein Based Nanostructures for Drug Delivery. J. Pharm. 2018, 9285854. DOI:10.1155/2018/9285854.
3. Zhang Y, Sun T, Jiang C. (2018). Biomacromolecules as Carriers in Drug Delivery and Tissue Engineering. Acta Pharm. Sin. B, 8 (1), 34–50. DOI:10.1016/j.apsb.2017.11.005.
4. Lee E J, Lee N K, Kim I S. Bioengineered Protein-Based Nanocage for Drug Delivery.Adv. Drug Deliv. Rev.2016, 106 (Pt A), 157–171. DOI:10.1016/j.addr.2016.03.002.
5. Salatin S, Jelvehgari M, Maleki-Dizaj S, Adibkia K. (2015) A Sight on Protein-Based Nanoparticles as Drug/Gene Delivery Systems. Ther. Deliv. 6 (8), 1017–1029. DOI:10.4155/tde.15.28.
6. Ferrer-Miralles N, Rodriguez-Carmona E, Corchero JL, et al. (2015) Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Crit Rev Biotechnol. 35(2):209–221.
7. Jeong Y, Jo YK, Kim BJ, Yang B, Joo KI, Cha HJ. (2018)Sprayable Adhesive Nanotherapeutics: Mussel-Protein-Based Nanoparticles for Highly Efficient Locoregional Cancer Therapy. ACS Nano. 2018;12(9):8909-8919. doi:10.1021/a. acsnano.8b04533
8. Lin X, Xie J, Zhu L, et al. (2011) Hybrid ferritin nanoparticles as activatable probes for tumor imaging. Angew Chem Int Ed Engl. 50(7):1569-1572. doi:10.1002/anie.201006757
9. Stromer BS, Roy S, Limbacher MR, et al. (2018). Multicolored Protein Nanoparticles: Synthesis, Characterization, and Cell Uptake. Bioconjug Chem.29(8):2576-2585. doi:10.1021/acs.biocoa. njchem.8b00282
10. Kim J, Grate JW. (2003). Single-enzyme nanoparticles armored by a nanometer-scale organic/inorganic network. Nano Letters. 3(9), pp. 1219-1222.
11. Sharma RK, Das S, Maitra A. (2005). Enzymes in the cavity of hollow silica nanoparticles. Author information. Journal of Colloid and Interface Science. 284(1):358-361. DOI: 10.1016/j.jcis.20
a. 04.10.006 PMID: 15752825
12. Tarpey I, Orbell S, Britton P, Casais R, Hodgson T, Lin F, et al. (2006) Safety and efficacy of an infectious bronchitis virus used for chicken embryo vaccination. Vaccine. 24: 6830–6838. Pmid: 16860445
13. Collisson EW, Pei J, Dzielawa J, Seo SH. (2000). Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Devea. lopmental & Comparative Immunology. 24:187-
14. Ladman B, Pope C, Ziegler A, Swieczkowski T, Callahan J, Davison S, et al. (2002). Protection of chickens after live and inactivated virus vaccination against challenge with enteropathogenic infectious bronchitis virus PA/Wolgemuth/98. Avian Dis. 46: 938–944. pmid:124950a. 55
15. Babapoor S, Almeida D, Fabis JJ, Helal Z, Wang X, Girshick T and Khan MI. (2009). Protective Effect of In ovo Vaccination with IBV-Spike Recombinant DNA and Chicken Interferon as an Adjuvant. Int. J. Poult Sci. 8 (11): 1034-1041.
16. Jackwood MW, Hilt DA. (1995). Production and immunogenicity of multiple antigenic peptide (MAP) constructs derived from S1 glycoprotein of infectious bronchitis virus (IBV). Adv Exp. Med. Biol. 380 213-219.
17. Wang X, Schnitzlein WM, Tripathy DN, Girshick T and Khan MI, (2001). Construction and immunogenicity studies of recombinant fowlpox virus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus. Avian Dis. 46: 831-838.
18. Wang L, Parr RL, King DJ, Collisson EW. (1995) A highly conserved epitope on the spike protein of infectious bronchitis virus. Archives of Virology. 140:12, pp 2201–2213.
19. Li J, Helal ZH, Karch CP, Mishra N, Girshick T, Garmendia A, et al. (2018). A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus. PLoS ONE. 13(9): e0203771. https://doi.org/10.1371/journal.pone.0203771
20. Kaba SA, Brando C, Guo Q, Mittelholzer C, Ra-man S, Tropel D, et al. (2009). A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol. ;183: 7268–7277. Pmid:19915055
21. Pimentel TA, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P. (2009). Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chemical biology & drug design. 73: 53–61.
22. Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, et al. (2011). A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection. Influenza Res Treat. 2011: 126794. pmid:23074652
23. Kaba SA, McCoy ME, Doll TA, Brando C, Guo Q, Dasgupta D, et al. Protective antibody and CD8 T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One. 2012;7:e4830 4. pmid:23144750
24. Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, Bosch V, et al. (2012). Conformation‐specific Display of 4E10 and 2F5 Epitopes on Self‐assembling Protein Nanoparticles as a Potential HIV Vaccine. Chemical biology & drug design. 80: 349–357.
25. El Bissati K, Zhou Y, Dasgupta D, Cobb D, Dubey JP, Burkhard P, et al. (2014). Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 32: 3243–3248. pmid:24736000
26. Thrane S, Janitzek CM, Agerbæk MØ, Ditlev SB, Resende M, Nielsen MA, et al. (2015). A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA. PLoS One. 10: e0143071. pmid:26599509
27. Karch CP, Li J, Kulangara C, Paulillo SM, Raman SK, Emadi S, et al. (2017). Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge. Nanomedicine: Nanotechnology, Biology and Medicine. 13: 241–251.
28. Lohcharoenkal W, Wang L, Chen Y C and Rojanasakul Y. (2014). Protein nanoparticles as drug delivery carriers for cancer therapy Biomed. Res. Int. 180549.
This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.